These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32930977)

  • 1. Electronic Reporting Systems in Pharmacovigilance: The Implementation of VigiFlow in Brazil.
    Vogler M; Ricci Conesa H; de Araújo Ferreira K; Moreira Cruz F; Simioni Gasparotto F; Fleck K; Maciel Rebelo F; Kollross B; Silveira Gonçalves Y
    Pharmaceut Med; 2020 Oct; 34(5):327-334. PubMed ID: 32930977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
    Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
    Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance in China: development and challenges.
    Zhao Y; Wang T; Li G; Sun S
    Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year.
    Singh P; Agrawal M; Hishikar R; Joshi U; Maheshwari B; Halwai A
    Indian J Pharmacol; 2017; 49(6):432-437. PubMed ID: 29674797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
    Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A
    Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spontaneous Adverse Drug Reaction Monitoring in a Tertiary Care Centre.
    Kaur K; Kanwal P; Goyal P; Singh P; Yakhmi S; Jain S; Kaushal S
    Curr Drug Saf; 2020; 15(3):215-221. PubMed ID: 32735525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial Intelligence in Pharmacovigilance and COVID-19.
    Bhardwaj K; Alam R; Pandeya A; Sharma PK
    Curr Drug Saf; 2023; 18(1):5-14. PubMed ID: 35382726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive intervention for adverse drug reactions identification and reporting in a Pediatric Emergency Department.
    Morales Ríos O; Jasso Gutiérrez L; Talavera JO; Téllez-Rojo MM; Olivar López V; Garduño Espinosa J; Muñoz Hernández O
    Int J Clin Pharm; 2016 Feb; 38(1):80-7. PubMed ID: 26499501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.
    Alroobaea R; Rubaiee S; Hanbazazah AS; Jahrami H; Garbarino S; Damiani G; Wu J; Bragazzi NL
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):4074-4081. PubMed ID: 35731078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active Pharmacovigilance Project on the safety profile of Dolutegravir in Brazil.
    Mendes JC; Ceccato MDGB; Reis AMM; Costa AMGD; Pantuzza LLN; Furtado Dos Santos S; Crepalde-Ribeiro K; Silveira MR
    AIDS Care; 2023 May; 35(5):729-738. PubMed ID: 35578399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
    Matos C; van Hunsel F; Joaquim J
    Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication.
    Varallo FR; Forgerini M; Herdeiro MT; de Carvalho Mastroianni P
    Clin Ther; 2019 Mar; 41(3):598-603. PubMed ID: 30792075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bulgarian Experience with Adverse Drug Reaction Reports from Patients and Consumers - Retrospective Data-base Study.
    Getova VI; Georgiev SR; Stoimenova AH; Petkova-Georgieva ES
    Folia Med (Plovdiv); 2018 Sep; 60(3):447-453. PubMed ID: 30355838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.
    Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study.
    Schutte T; Tichelaar J; Reumerman MO; van Eekeren R; Rolfes L; van Puijenbroek EP; Richir MC; van Agtmael MA
    Drug Saf; 2017 May; 40(5):409-418. PubMed ID: 28120270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
    Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B
    Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance.
    Bahri P; Dodoo AN; Edwards BD; Edwards IR; Fermont I; Hagemann U; Hartigan-Go K; Hugman B; Mol PG
    Drug Saf; 2015 Jul; 38(7):621-7. PubMed ID: 26032946
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.